Study guide
7.2 Clinical Risk Reduction, VTE Prophylaxis & Infection Prevention
Cardiac-Vascular Nursing CV-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 ANCC CV-BC Certification Facts & Exam Overview 1.2 Clinical Reasoning & Study Strategies for Cardiac Nurses
2 Chapter 2: Cardiac Anatomy, Electrophysiology & Pathophysiology
2.1 Cardiac Anatomy, Electrophysiology & Hemodynamics 2.2 Pathophysiology of CAD, ACS & Heart Failure Syndromes 2.3 Valvular Disorders, Vascular Diseases & Aortic Pathologies
3 Chapter 3: Assessment, Diagnostic Modalities & Nursing Diagnoses
3.1 Nursing Diagnosis Identification & Clinical Decision Making 3.2 Patient Interview, Symptom Analysis & Social Determinants 3.3 Physical Examination Techniques, Heart Sounds & Bedside Tools 3.4 Diagnostic Tests, Lab Biomarkers & ECG Rhythm Analysis
4 Chapter 4: Evidence-Based Guidelines, Nursing Scope & Ethics
4.1 Evidence-Based Practice Guidelines & Quality Measures 4.2 Cardiovascular Nursing Scope & Professional Standards 4.3 Informed Consent, Advance Directives & Ethical Dilemmas
5 Chapter 5: Catheterization, Surgical Procedures & Mechanical Circulatory Support
5.1 Cardiac Catheterization, Percutaneous Interventions & Structural Heart 5.2 Coronary Bypass, Surgical Valve Repair & Vascular Revascularization 5.3 Mechanical Circulatory Support (LVAD, IABP, ECMO) & Heart Transplantation
6 Chapter 6: Cardiovascular Pharmacotherapy
6.1 Inotropes, Vasopressors & Vasoactive Infusions 6.2 Antihypertensives & Guideline-Directed Heart Failure Therapies 6.3 Antithrombotic Agents, Antiarrhythmics & Lipid Management
7 Chapter 7: Interventions, Risk Reduction & Clinical Coordination
7.1 Non-Pharmacologic Therapies, Cardiac Nutrition & Exercise 7.2 Clinical Risk Reduction, VTE Prophylaxis & Infection Prevention 7.3 Interdisciplinary Coordination, Targeted Temperature Management & Cardioversion
8 Chapter 8: Outcome Evaluation, Drug Interactions & Complication Management
8.1 Evaluating Expected Outcomes & Managing Cardiovascular Drug Interactions 8.2 Recognition and Treatment of Adverse Reactions & Clinical Complications
9 Chapter 9: Urgent & Emergent Cardiovascular Crises
9.1 Recognition and Treatment of Urgent Cardiovascular Conditions 9.2 Recognition and Immediate Management of Emergent Cardiovascular Crises 9.3 Cardiogenic Shock, Cardiac Tamponade & Cardiac Arrest Resuscitation
10 Chapter 10: Chronic Disease Management, Risk Factors & Patient Education
10.1 Cardiovascular Risk Factors, Epidemiology & Health Disparities 10.2 Long-Term Management of Chronic Cardiovascular Diseases 10.3 Essential Patient & Family Educational Topics 10.4 Self-Management Strategies, Home Monitoring & Symptom Action Plans
11 Chapter 11: Health Literacy, Cardiac Rehabilitation & Outpatient Services
11.1 Individualized Education Planning, Health Literacy & Cultural Competence 11.2 Community Resources, Cardiac Rehabilitation & Outpatient Services 11.3 Outpatient Telemetry, Remote Monitoring & Community Health Promotion
7.2 Clinical Risk Reduction, VTE Prophylaxis & Infection Prevention
Key Takeaways Explain This Topic AI
Hospital-acquired venous thromboembolism (VTE) risk must be objectively quantified using validated scoring models: the Padua Prediction Score (high risk ≥4) for hospitalized medical patients and the Caprini Risk Assessment Model (moderate 2, high 3-4, highest ≥5) for surgical patients.
Pharmacologic thromboprophylaxis with low-molecular-weight heparin (enoxaparin 40 mg SC daily or 30 mg SC q12h) or low-dose unfractionated heparin (LDUH 5,000 units SC q8-12h) is standard; enoxaparin requires dose reduction to 30 mg SC daily when CrCl falls below 30 mL/min, with LDUH preferred in end-stage renal disease.
Mechanical prophylaxis with sequential compression devices (SCDs) accelerates femoral venous blood flow and promotes endogenous tPA release; it is mandatory when anticoagulation is contraindicated, but is strictly contraindicated in patients with severe peripheral artery disease (ABI <0.5), acute DVT/PE, or open cutaneous ulcerations.
Healthcare-associated infection (HAI) bundles require rigorous execution: the CLABSI bundle prioritizes chlorhexidine skin prep with friction, maximal sterile barriers, subclavian site selection, and daily catheter necessity review; CAUTI prevention requires strict clinical indications and closed dependent drainage; and SSI reduction mandates electric clippers (never razors), normothermia, and blood glucose <180 mg/dL.
AHA/ACC infective endocarditis (IE) antibiotic prophylaxis is strictly restricted to highest-risk cardiac conditions (prosthetic heart valves, prosthetic repair material, prior IE, unrepaired or incompletely repaired cyanotic congenital heart disease, or heart transplant with valvulopathy) undergoing dental procedures involving gingival or periapical manipulation; the standard oral regimen is amoxicillin 2.0 g PO 30 to 60 minutes prior.
Last updated: September 2026
7.2 Clinical Risk Reduction, VTE Prophylaxis & Infection Prevention
Note
ANCC Blueprint Focus : Hospital-acquired complications represent major sources of preventable morbidity, mortality, and financial penalty in cardiovascular nursing practice. ANCC exam items assess the nurse's expertise in applying validated VTE risk models, adjusting anticoagulants for renal insufficiency, recognizing contraindications to mechanical compression devices, adhering to CLABSI and CAUTI prevention bundles, and selecting patients who require endocarditis antibiotic prophylaxis.
Preventing hospital-acquired complications requires a proactive, bundle-driven nursing approach. In cardiovascular units, where patients frequently present with multi-organ comorbidities, indwelling vascular devices, and surgical wounds, rigorous risk stratification directly protects against catastrophic thromboembolic and infectious events.
Hospital-Acquired VTE Risk Assessment & Stratification
Hospital-acquired venous thromboembolism (comprising deep vein thrombosis [DVT] and pulmonary embolism [PE]) is the leading preventable cause of in-hospital death. Systematic risk stratification at admission and with any clinical change is mandatory.
Clinical Risk Assessment Models
The Padua Prediction Score (Hospitalized Medical Patients) :
Validated for acute medical admissions (e.g., heart failure, ACS, pneumonia).
High VTE Risk is defined as a cumulative score ≥ 4 \ge 4 ≥ 4 , indicating a clear mandate for pharmacologic thromboprophylaxis.
Scoring criteria: Active cancer (3 points); previous VTE (3 points); reduced mobility / bed rest with bathroom privileges for ≥ 3 \ge 3 ≥ 3 days (3 points); known thrombophilia (3 points); recent trauma or surgery ≤ 1 \le 1 ≤ 1 month (2 points); age ≥ 70 \ge 70 ≥ 70 years (1 point); heart or respiratory failure (1 point); acute myocardial infarction or ischemic stroke (1 point); acute infection or rheumatologic disorder (1 point); obesity with BMI ≥ 30 kg/m 2 \text{BMI} \ge 30\text{ kg/m}^2 BMI ≥ 30 kg/m 2 (1 point); ongoing hormonal therapy (1 point).
The Caprini Risk Assessment Model (Surgical & Cardiovascular Patients) :
Widely utilized in cardiac surgery (CABG, valve replacement) and vascular procedures.
Categorizes surgical patients into: Low Risk (0–1 point: early ambulation alone); Moderate Risk (2 points: mechanical or pharmacologic prophylaxis); High Risk (3–4 points: pharmacologic prophylaxis +/- mechanical); and Highest Risk ( ≥ 5 \ge 5 ≥ 5 points: dual pharmacologic and mechanical prophylaxis continued post-discharge).
Pharmacologic & Mechanical Thromboprophylaxis
Balancing thromboprophylaxis efficacy against surgical and systemic bleeding risk is a core nursing responsibility.
Prophylactic Modality Standard Dosing & Administration Renal Adjustments & Laboratory Surveillance Clinical Indications & Nursing Considerations
Enoxaparin (LMWH / Lovenox) 40 mg SC once daily (or 30 mg SC q12h in high-risk trauma/orthopedics). Administer subcutaneously into anterolateral/posterolateral abdominal wall. Renal Impairment : When CrCl < 30 mL/min \text{CrCl} < 30\text{ mL/min} CrCl < 30 mL/min , reduce dose to 30 mg SC once daily . Avoid in End-Stage Renal Disease (ESRD) on hemodialysis due to bioaccumulation. First-line agent in medical and non-cardiac surgical patients. Lower incidence of Heparin-Induced Thrombocytopenia (HIT) compared to unfractionated heparin. Do not expel air bubble from prefilled syringe before injection.
Low-Dose Unfractionated Heparin (LDUH) 5,000 units SC every 8 or 12 hours . No renal adjustment required . Cleared predominantly via reticuloendothelial system and endothelial cells. Preferred agent in severe renal failure ( CrCl < 15 mL/min \text{CrCl} < 15\text{ mL/min} CrCl < 15 mL/min or dialysis) and when rapid reversibility is required (protamine sulfate completely neutralizes heparin within minutes).
Fondaparinux (Arixtra) 2.5 mg SC once daily . Synthetic selective Factor Xa inhibitor. Strictly contraindicated if CrCl < 30 mL/min \text{CrCl} < 30\text{ mL/min} CrCl < 30 mL/min . Safe and effective alternative in patients with a verified history of Heparin-Induced Thrombocytopenia (HIT). Has zero cross-reactivity with HIT antibodies.
Sequential Compression Devices (SCDs) Applied bilaterally to lower extremities; cyclical pneumatic inflation to 35 to 55 mmHg . No laboratory monitoring; inspect skin integrity beneath sleeves every 8 hours. Augments peak venous velocity, reduces venous stasis, and stimulates endothelial release of tissue plasminogen activator (tPA). First-line when pharmacologic prophylaxis is contraindicated.
Heparin-Induced Thrombocytopenia (HIT) Surveillance
Mechanism : Immune-mediated adverse drug reaction caused by IgG antibodies directed against platelet factor 4 (PF4)-heparin complexes. These complexes bind to platelet Fc receptors, triggering massive platelet activation, thrombin generation, and catastrophic arterial and venous thrombosis (HIT-thrombosis syndrome).
Monitoring Protocol : Obtain baseline platelet count before initiating heparin or LMWH. Monitor platelet counts every 2 to 3 days from day 4 to day 14 of therapy (or within 24 hours if heparin was received in the preceding 100 days).
The '4 Ts' Diagnostic Rule : Clinical suspicion must be triggered if the platelet count drops by ≥ 50 % \ge 50\% ≥ 50% from baseline or falls below 100 , 000 / μ L 100,000/\mu\text{L} 100 , 000/ μ L , even if the absolute nadir remains above 150 , 000 / μ L 150,000/\mu\text{L} 150 , 000/ μ L .
Immediate Nursing Actions :
Immediately discontinue all heparin sources (including subcutaneous prophylactic doses, IV infusions, heparin line flushes, and heparin-coated vascular catheters).
Never administer low-molecular-weight heparin as a substitute (cross-reactivity > 90 % >90\% > 90% ).
Avoid platelet transfusions (which add fuel to the prothrombotic fire).
Initiate a non-heparin parenteral direct thrombin inhibitor (argatroban or bivalirudin) or fondaparinux.
Contraindications to Mechanical Compression Devices (SCDs / GCS)
Mechanical compression is vital when bleeding risks preclude anticoagulation, but the nurse must identify critical contraindications:
Severe Peripheral Artery Disease (PAD) : Ankle-brachial index (ABI) < 0.5 <0.5 < 0.5 , absent pedal pulses, or severe ischemic rest pain. External compression on severely stenotic or calcified arterial beds provokes microvascular occlusion, acute skin necrosis, and limb-threatening ischemia.
Known or Suspected Acute DVT / PE : Applying pneumatic compression over an existing, non-stabilized deep venous thrombus can dislodge the clot and precipitate a fatal pulmonary embolism.
Severe Peripheral Edema / Acute Congestive Heart Failure : Sudden compression and mobilization of large volumes of peripheral third-space fluid into the central circulation can acutely elevate left ventricular preload and trigger flash pulmonary edema.
Local Cutaneous Pathology : Active severe dermatitis, open leg ulcers, gangrene, recent skin graft, or extreme lower extremity deformity.
Device-Related Infection Prevention: CLABSI, CAUTI & SSI Bundles
Healthcare-associated infections (HAIs) are largely preventable through strict adherence to standardized clinical practice bundles.
1. Central Line-Associated Bloodstream Infection (CLABSI) Bundle
Insertion Protocol :
Rigorous hand hygiene prior to catheter insertion and site manipulation.
Maximal Sterile Barrier Precautions : Mask, cap, sterile gown, sterile gloves, and a full-body sterile drape covering the patient from head to toe.
Skin Antisepsis : Alcoholic chlorhexidine gluconate solution ( >0.5% chlorhexidine with 70% isopropyl alcohol ). Apply with vigorous back-and-forth friction for at least 30 seconds; allow to air-dry completely (minimum 2 minutes) before venipuncture (chlorhexidine requires dry contact time for bactericidal action).
Anatomical Site Selection : The subclavian vein is the preferred site for non-tunneled central venous lines due to the lowest rate of infectious and thrombotic complications. The internal jugular vein is acceptable (though higher risk due to tracheostomy/oral secretions). The femoral vein should be strictly avoided in adult patients due to high microbial colonization and deep vein thrombosis risks.
Maintenance Protocol :
'Scrub the hub': Vigorously scrub catheter hubs, needleless connectors, and injection ports with chlorhexidine or 70% alcohol for at least 15 seconds (or utilize chlorhexidine-impregnated protective caps) prior to every access.
Change transparent semipermeable membrane dressings every 7 days (or every 48 hours for gauze dressings), and immediately if the dressing becomes damp, loose, or visibly soiled.
Daily Line Review : The nurse must evaluate catheter necessity on daily multidisciplinary rounds and advocate for immediate line removal when clear clinical indication ceases.
2. Catheter-Associated Urinary Tract Infection (CAUTI) Bundle
Appropriate Indications : Urinary catheters must never be placed for convenience or routine incontinence management. Legitimate indications are restricted to: acute urinary retention or bladder outlet obstruction; precise hourly urine volume monitoring in hemodynamically unstable intensive care patients; open Stage 3 or 4 perineal/sacral pressure injuries in incontinent patients; prolonged surgical procedures; and comfort measures in end-of-life care.
Aseptic Maintenance : Perform hand hygiene and insert using strict sterile technique with a small-bore catheter (14 to 16 French). Maintain a continuously closed drainage system .
Gravity & Positioning : Keep the collection bag continuously below the level of the patient's bladder to prevent retrograde flow of colonized urine. Secure the catheter to the thigh to eliminate traction and urethral mucosal trauma. Ensure tubing remains free of dependent loops, kinks, and floor contact.
Prompt Removal : Remove indwelling catheters within 24 to 48 hours postoperatively in cardiac surgical patients unless hemodynamic instability mandates continued hourly output titration.
3. Surgical Site Infection (SSI) Reduction Bundle
Perioperative Glycemic Control : Maintain target perioperative blood glucose < 180 mg/dL <180\text{ mg/dL} < 180 mg/dL (10.0 mmol/L) in both diabetic and non-diabetic cardiac surgery patients (CABG, valve replacement). Hyperglycemia severely suppresses neutrophil chemotaxis, phagocytosis, and bactericidal oxidative burst.
Maintenance of Normothermia : Maintain core body temperature ≥ 36.0 ∘ C \ge 36.0^\circ\text{C} ≥ 36. 0 ∘ C ( 96.8 ∘ F 96.8^\circ\text{F} 96. 8 ∘ F ) throughout the intraoperative and immediate postoperative phases using active forced-air warming blankets. Hypothermia induces peripheral vasoconstriction, diminishes tissue oxygen tension at the surgical incision, and impairs platelet aggregation.
Hair Removal Standard : If hair removal at the surgical site is necessary, use electric surgical clippers with a single-use disposable head immediately prior to surgery in the pre-op holding area. Manual razors are strictly prohibited because razor blades create microscopic cutaneous abrasions and epidermal micro-lacerations that become rapidly colonized by Staphylococcus aureus and skin flora.
Antimicrobial Prophylaxis Timing & Dosing : Administer weight-adjusted prophylactic antibiotics (e.g., Cefazolin 2.0 g IV for < 120 kg <120\text{ kg} < 120 kg , or 3.0 g IV for ≥ 120 kg \ge 120\text{ kg} ≥ 120 kg ) within 60 minutes prior to surgical incision (or within 120 minutes for vancomycin/fluoroquinolones). Re-dose intraoperatively if surgery exceeds 4 hours or blood loss exceeds 1,500 mL. Discontinue all prophylactic antibiotics within 24 to 48 hours post-cardiac surgery.
Infective Endocarditis (IE) Antibiotic Prophylaxis Guidelines
Contemporary American Heart Association / American College of Cardiology (AHA/ACC) guidelines strictly restrict antibiotic prophylaxis prior to dental procedures to only those patients at the highest risk of adverse outcomes from infective endocarditis. [ High-Risk Cardiac Condition Present? ]
- │
- ┌──────────────────────┴──────────────────────┐
- │ YES │ NO
- ▼ ▼
- 1. Prosthetic heart valves (mechanical, NO PROPHYLAXIS REQUIRED
- bioprosthetic, homograft, TAVR/TMVR) (Native MVP, bicuspid aortic
- 2. Prosthetic material for valve repair valve, calcific AS, innocent
- (annuloplasty rings, clips, chords) murmurs, pacemakers, ICDs,
- 3. Previous episode of Infective Endocarditis or coronary artery stents)
4. Congenital Heart Disease (CHD):
- Unrepaired cyanotic CHD (shunts)
- Repaired CHD with prosthetic material
- during first 6 months post-procedure
- Repaired CHD with residual defects at/near
- site of prosthetic patch/device
- 5. Cardiac transplant recipients with valvulopathy
- │
- ▼
- [ Undergoing Dental Procedure Involving: ]
- Gingival tissue manipulation
- Periapical region of teeth manipulation
- Perforation of the oral mucosa
- │
- ▼
- [ Guideline Antibiotic Regimen (30-60 min Pre-Procedure) ]
- Standard Oral: Amoxicillin 2.0 g PO
- Unable to take PO: Ampicillin 2.0 g IM/IV or Cefazolin 1.0 g IM/IV
- Penicillin-Allergic: Cephalexin 2.0 g PO, Azithromycin/Clarithromycin 500 mg PO
- *(Clindamycin is NO LONGER recommended due to C. difficile risk)*
- Critical Clinical Points on Endocarditis Prophylaxis
Conditions NOT Requiring Prophylaxis : Native valvular heart disease (such as mitral valve prolapse with or without regurgitation, bicuspid aortic valve, calcific aortic stenosis), hypertrophic cardiomyopathy, innocent heart murmurs, ventricular septal defects repaired without prosthetic material after 6 months, coronary artery stents, and implanted pacemakers or ICDs.
Procedures NOT Requiring Prophylaxis : Routine dental anesthetic injections through non-infected tissue, taking dental radiographs, placement of removable prosthodontic appliances, shedding of deciduous teeth, and bleeding from trauma to the lips or oral mucosa.
The Removal of Clindamycin : In 2021, the AHA officially removed clindamycin from the recommended prophylaxis regimens for penicillin-allergic patients due to its substantial risk of inducing lethal Clostridioides difficile colitis and increasing resistance among viridans group streptococci.